Anavex Life Sciences (AVXL) vs NRX Pharmaceuticals (NRXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
NRX Pharmaceuticals (NRXP) has outperformed Anavex Life Sciences (AVXL) over the past year, losing 18.2% versus a loss of 85.4%. Over five years, AVXL leads with a -92.7% price change compared with -97.4% for NRXP. Anavex Life Sciences is the larger company by market cap ($121.4 million vs $112.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVXL | NRXP |
|---|---|---|
| Share price | $1.31 | $2.60 |
| Market cap | $121.43M | $112.57M |
| 1-day change | -11.49% | -4.06% |
| YTD return | -63.20% | -4.06% |
| 1-year return | -85.41% | -18.24% |
| 5-year return | -92.66% | -97.37% |
| EPS (TTM) | $-0.14 | $-0.58 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $1.23M |
| Net income (latest FY) | $-46.38M | $-28.62M |
| Gross margin | — | 58.78% |
| Operating margin | — | -1324.41% |
| Net margin | — | -2336.49% |
| 52-week high | $9.50 | $5.06 |
| 52-week low | $1.30 | $1.62 |
| Distance from 52-week high | -86.21% | -48.57% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | — | +1380.77% |
| Average volume | 1.01M | 860.32K |
| Shares outstanding | 92.70M | 43.30M |
| Employees | 34 | 29 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXP has outperformed AVXL by 67.2 percentage points over the past year.
About Anavex Life Sciences
AVXL stock →Anavex Life Sciences Corp. operates as a biopharmaceutical company.
Healthcare · Biotechnology · 34 employees
About NRX Pharmaceuticals
NRXP stock →NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments.
Healthcare · Biotechnology · 29 employees
AVXL vs NRXP FAQ
Which is bigger, Anavex Life Sciences or NRX Pharmaceuticals?
Anavex Life Sciences (AVXL) is larger, with a market capitalization of $121.43M compared with $112.57M for NRX Pharmaceuticals (NRXP).
Which stock has performed better over the past year, AVXL or NRXP?
NRXP returned -18.24% over the past 12 months, compared with -85.41% for AVXL (price return, excluding dividends). Past performance does not predict future results.
Are Anavex Life Sciences and NRX Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.